By Sheri Kasprzak
Des Moines, Oct. 10 - Dynavax Technologies Corp. settled its previously announced private placement, with a fully exercised greenshoe bringing the total deal size to $31.372 million.
The deal priced on Oct. 4 as a $27.28 million placement.
The company sold 7.13 million shares, including the greenshoe for 930,000 shares, at $4.40 each.
The shares were sold under the company's shelf registration.
Pacific Growth Equities, LLC was the underwriter.
Dynavax, based in Berkeley, Calif., develops treatments for cancer and allergies, and it is developing a vaccine for hepatitis B.
| Issuer: | Dynavax Technologies Corp.
|
| Issue: | Stock
|
| Amount: | $31.372 million
|
| Shares: | 7.13 million (includes greenshoe for 930,000 shares)
|
| Price: | $4.40
|
| Warrants: | No
|
| Underwriter: | Pacific Growth Equities, LLC
|
| Pricing date: | Oct. 4
|
| Settlement date: | Oct. 10
|
| Stock symbol: | Nasdaq: DVAX
|
| Stock price: | $4.40 at close Oct. 3
|
| Stock price: | $7.15 at close Oct. 10
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
